Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044078 | 0.91 | KDM4E (0.52) | MAOBKDM4EALDH1A1TAAR1NOS1 | |
| SCHEMBL6088496 | 0.87 | MAOB (0.51) | MAOBKDM4EALDH1A1TAAR1NOS1 | |
| SCHEMBL26985792 | 0.86 | TAAR1 (0.67) | MAOBKDM4EALDH1A1TAAR1 | |
| SCHEMBL20553118 | 0.85 | KDM4E (0.48) | MAOBKDM4ETAAR1NOS1NOS2 | |
| SCHEMBL6489910 | 0.84 | MAOB (0.54) | MAOBTAAR1NOS1NOS2LOXL2 | |
| SCHEMBL2538910 | 0.84 | DHFR (0.54) | MAOBKDM4EALDH1A1TAAR1NOS1 | |
| SCHEMBL4487459 | 0.84 | KDM4E (0.68) | KDM4EALDH1A1MAPK1CYP1A2CYP2D6 | |
| SCHEMBL2207482 | 0.83 | TAAR1 (0.54) | MAOBKDM4EALDH1A1TAAR1MAPK1 | |
| SCHEMBL12408537 | 0.83 | PRSS1 (0.51) | MAOBKDM4EALDH1A1NOS1NOS2 | |
| SCHEMBL15723552 | 0.82 | MAPK1 (0.58) | MAOBKDM4EALDH1A1MAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4384516-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | Texas Heart Institute (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240139164-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-05-02 | — | — | US | disclosed |
| US-20240131012-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-25 | — | — | US | disclosed |
| CN-117916237-A | Amino aryl integrin agonist compounds | 德克萨斯心脏研究所 | 2024-04-19 | — | — | CN | disclosed |
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-11819476-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11819476-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11819476-B2 | Rapamycin analogs and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| WO-2023018472-A9 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-07-13 | — | — | WO | disclosed |
| US-9221808-B2 | Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130059839-A1 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2012135697-A2 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2011130740-A2 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-7825253-B2 | 2-aminoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2076495-B1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | HOFFMANN LA ROCHE (CH) | 2010-08-18 | — | — | EP | disclosed |
| EP-2076495-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | disclosed |
| WO-2008037626-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | YAP1, MYC, TEAD2 | MAOB 3869/4885KDM4E 1683/4885ALDH1A1 2731/4885 |
| US-20140179689-A1 | NOVEL RHO KINASE INHIBITORS AND METHODS OF USE | ROCK1, ROCK2, RHOA | MAOB 1469/4885KDM4E 1273/4885ALDH1A1 3573/4885 |
| US-20240139164-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | MAOB 4115/4885KDM4E 1565/4885ALDH1A1 4627/4885 |
| US-20130059839-A1 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | ROCK1, ROCK2, CIT | MAOB 1132/4885KDM4E 1134/4885ALDH1A1 4453/4885 |
| US-20240131012-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | MAOB 4115/4885KDM4E 1565/4885ALDH1A1 4627/4885 |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | AR, ADRA2C, RCC2 | MAOB 1669/4885KDM4E 1488/4885ALDH1A1 872/4885 |
| US-11819476-B2 | Rapamycin analogs and uses thereof | RICTOR, MTOR, RPTOR | MAOB 4268/4885KDM4E 1179/4885ALDH1A1 4445/4885 |
| US-20240360113-A1 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | ITGB3, ITGA2, ITGAV | MAOB 2688/4885KDM4E 3592/4885ALDH1A1 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.